Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease

Pulmonary Circulation

Volumn 4, Issue 1, 2014, Pages 128-136

  Kosanovic, Djuro ^a   Dahal, Bhola Kumar ^a   Peters, Dorothea Maren ^a   Seimetz, Michael ^a   Wygrecka, Malgorzata ^a   Hoffmann, Katrin ^b   Antel, Jochen ^b   Reiss, Irwin ^c   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a   Grimminger, Friedrich ^a   Seeger, Werner ^a,d   Schermuly, Ralph Theo ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Chymase; Idiopathic pulmonary arterial hypertension; Mast cells

Indexed keywords

EID: 85026336613     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/675642     Document Type: Article

References (34)

1. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S20-S31.
2. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-2379.
3. Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, Milger K, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011;147:293-305.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
5. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
6. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008;49:7-19.
7. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 2007;217:304-328.
8. Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 2004;61:653-662.
9. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006;112:668-676.
10. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and promatrix metalloprotease-2. J Biol Chem 2005;280:9291-9296.
11. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003-1006.
12. Mitani Y, Ueda M, Maruyama K, Shimpo H, Kojima A, Matsumura M, Aoki K, Sakurai M. Mast cell chymase in pulmonary hypertension. Thorax 1999;54:88-90.
13. Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997;151:1785-1790.
14. Wang T, Han SX, Zhang SF, Ning YY, Chen L, Chen YJ, He GM, et al. Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res 2010;11:36.
15. Gosman MME, Postma DS, Vonk JM, Rutgers B, Lodewijk M, Smith M, Luinge MA, ten Hacken NHT, Timens W. Association of mast cells with lung function in chronic obstructive pulmonary disease. Respir Res 2008;9:64.
16. Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, Mutti E, Hogg JC, Saetta M, Cosio MG. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:233-239.
17. Farha S, Sharp J, Asosingh K, Park M, Comhair SAA, Tang WHW, Thomas J, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2012;2:220-228.
18. Soltani A, Ewe YP, Lim ZS, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH. Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. Eur Respir J 2012;39:1361-1367.
19. Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011;12:60.
20. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36:808-818.
21. Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang S-K, Bieber J, Chi DS. The human mast cell: functions in physiology and disease. Front Biosci 2001;6: 1109-1127.
22. Trivedi NN, Caughey GH. Mast cell peptidases: chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol 2010;42:257-267.
23. Palaniyandi SS, Inagaki K, Mochly-Rosen D. Mast cells and εPKC: a role in cardiac remodeling in hypertensioninduced heart failure. J Mol Cell Cardiol 2008;45:779-786.
24. Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med 1999;160:1303-1308.
25. Miyazaki M, Takai S. Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res 2001;24:189-193.
26. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, Tsutsui H, Yamanishi K, Nakanishi K, Mizutani H. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006;177:8315-8319.
27. Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 2004;501: 1-8.
28. Wypij DM, Nichols JS, Novak PJ, Stacy DL, Berman J, Wiseman JS. Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992;43:845-853.
29. Kosanovic D, Dahal BK, Wygrecka M, Reiss I, Guünther A, Ghofrani HA, Weissmann N, et al. Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Histol Histopathol 2013;28: 691-699.
30. D’Orléans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E. Endothelin-1 (1-31): fromchymase-dependent synthesis to cardiovascular pathologies. Vasc Pharmacol 2008; 49:51-62.
31. Chhabra SK. Pulmonary hypertension associated with chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2010;52:29-40.
32. Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M. Simultaneous up-regulation of matrix metalloproteinases 1,2,3,7,8,9 and tissue inhibitors of metalloproteinases 1,4 in serum of patients with chronic obstructive pulmonary disease. Respirology 2012;17:1006-1012.
33. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 2007;176:49-62.
34. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T, Kato S, Iwasaki H, Watanabe K, Aizawa H. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 2008;31:287-297.